These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21255829)

  • 1. Combination therapy for visceral leishmaniasis.
    van Griensven J; Boelaert M
    Lancet; 2011 Feb; 377(9764):443-4. PubMed ID: 21255829
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study.
    Pandey K; Pal B; Das VNR; Murti K; Lal CS; Verma N; Bimal S; Ali V; Verma RB; Topno RK; Siddiqi NA; Das P
    Br J Dermatol; 2017 Aug; 177(2):557-559. PubMed ID: 27781268
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
    Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral leishmaniasis: elimination with existing interventions.
    Matlashewski G; Arana B; Kroeger A; Battacharya S; Sundar S; Das P; Sinha PK; Rijal S; Mondal D; Zilberstein D; Alvar J
    Lancet Infect Dis; 2011 Apr; 11(4):322-5. PubMed ID: 21453873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.
    Goyal V; Mahajan R; Pandey K; Singh SN; Singh RS; Strub-Wourgaft N; Alves F; Rabi Das VN; Topno RK; Sharma B; Balasegaram M; Bern C; Hightower A; Rijal S; Ellis S; Sunyoto T; Burza S; Lima N; Das P; Alvar J
    PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006830. PubMed ID: 30346949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.
    Olliaro P; Darley S; Laxminarayan R; Sundar S
    Trop Med Int Health; 2009 Aug; 14(8):918-25. PubMed ID: 19563434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies.
    Rodrigo C; Weeratunga P; Fernando SD; Rajapakse S
    Clin Microbiol Infect; 2018 Jun; 24(6):591-598. PubMed ID: 29138100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ambisome plus miltefosine for Indian patients with kala-azar.
    Sundar S; Sinha PK; Verma DK; Kumar N; Alam S; Pandey K; Kumari P; Ravidas V; Chakravarty J; Verma N; Berman J; Ghalib H; Arana B
    Trans R Soc Trop Med Hyg; 2011 Feb; 105(2):115-7. PubMed ID: 21129762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.
    Meheus F; Balasegaram M; Olliaro P; Sundar S; Rijal S; Faiz MA; Boelaert M
    PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20838649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-course of oral miltefosine for treatment of visceral leishmaniasis.
    Sundar S; Makharia A; More DK; Agrawal G; Voss A; Fischer C; Bachmann P; Murray HW
    Clin Infect Dis; 2000 Oct; 31(4):1110-3. PubMed ID: 11049800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
    Olliaro P; Sundar S
    Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy.
    Kumar N; Sinha PK; Pandey K; Verma N; Lal CS; Ranjan A; Verma RB; Das P
    Int J Clin Pharm; 2011 Oct; 33(5):726-9. PubMed ID: 21833710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP; Marty P
    Sante; 2001; 11(4):257-8. PubMed ID: 11861203
    [No Abstract]   [Full Text] [Related]  

  • 19. Retrospective Quarterly Cohort Monitoring for patients with Visceral Leishmaniasis in the Indian subcontinent: outcomes of a pilot project.
    Ostyn B; Malaviya P; Hasker E; Uranw S; Singh RP; Rijal S; Sundar S; Dujardin JC; Boelaert M
    Trop Med Int Health; 2013 Jun; 18(6):725-33. PubMed ID: 23464638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
    Wasunna M; Njenga S; Balasegaram M; Alexander N; Omollo R; Edwards T; Dorlo TP; Musa B; Ali MH; Elamin MY; Kirigi G; Juma R; Kip AE; Schoone GJ; Hailu A; Olobo J; Ellis S; Kimutai R; Wells S; Khalil EA; Strub Wourgaft N; Alves F; Musa A
    PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.